Literature DB >> 24486290

Variation in the intensity of hematuria evaluation: a target for primary care quality improvement.

David F Friedlander1, Matthew J Resnick2, Chaochen You3, Jeffrey Bassett3, Vidhush Yarlagadda4, David F Penson2, Daniel A Barocas5.   

Abstract

BACKGROUND: Hematuria is a common clinical finding and represents the most frequent presenting sign of bladder cancer. The American Urological Association recommends cystoscopy and abdomino-pelvic imaging for patients aged more than 35 years. Nonetheless, less than half of patients presenting with hematuria undergo proper evaluation. We sought to identify clinical and nonclinical factors associated with evaluation of persons with newly diagnosed hematuria.
METHODS: We performed a retrospective cohort study, using claims data and laboratory values. The primary exposure was practice site, as a surrogate for nonclinical, potentially modifiable sources of variation. Primary outcomes were cystoscopy or abdomino-pelvic imaging within 180 days after hematuria diagnosis. We modeled the association between clinical and nonclinical factors and appropriate hematuria evaluation.
RESULTS: We identified 2455 primary care patients aged 40 years or more and diagnosed with hematuria between 2004 and 2012 in the absence of other explanatory diagnosis; 13.7% of patients underwent cystoscopy within 180 days. Multivariate logistic regression revealed significant variation between those who did and did not undergo evaluation in age, gender, and anticoagulant use (P < .001, P = .036, P = .028, respectively). Addition of practice site improved the predictive discrimination of each model (P < .001). Evaluation was associated with a higher rates of genitourinary neoplasia diagnosis.
CONCLUSIONS: Patients with hematuria rarely underwent complete evaluation. Although established risk factors for malignancy were associated with increasing use of diagnostic testing, factors unassociated with risk, such as practice site, also accounted for significant variation. Inconsistency across practice sites is undesirable and may be amenable to quality improvement interventions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic test; Guideline adherence; Hematuria; Quality of health care; Routine; Urinary bladder neoplasms

Mesh:

Year:  2014        PMID: 24486290      PMCID: PMC4074456          DOI: 10.1016/j.amjmed.2014.01.010

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology.

Authors:  G D Grossfeld; M S Litwin; J S Wolf; H Hricak; C L Shuler; D C Agerter; P R Carroll
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

Review 2.  Asymptomatic microscopic or dipstick haematuria in adults: which investigations for which patients? A review of the evidence.

Authors:  C Tomson; T Porter
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

3.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

4.  Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system.

Authors:  Faysal A Yafi; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

5.  Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline.

Authors:  Rodney Davis; J Stephen Jones; Daniel A Barocas; Erik P Castle; Erich K Lang; Raymond J Leveillee; Edward M Messing; Scott D Miller; Andrew C Peterson; Thomas M T Turk; William Weitzel
Journal:  J Urol       Date:  2012-10-24       Impact factor: 7.450

6.  Tobacco smoking and cancer: a meta-analysis.

Authors:  Sara Gandini; Edoardo Botteri; Simona Iodice; Mathieu Boniol; Albert B Lowenfels; Patrick Maisonneuve; Peter Boyle
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

7.  Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey.

Authors:  Alan M Nieder; Yair Lotan; Geoffrey R Nuss; Joshua P Langston; Sachin Vyas; Murugesan Manoharan; Mark S Soloway
Journal:  Urol Oncol       Date:  2008-12-20       Impact factor: 3.498

8.  The value of urine screening in a young adult population.

Authors:  Peter S Topham; Ashok Jethwa; Maggie Watkins; Yvonne Rees; John Feehally
Journal:  Fam Pract       Date:  2004-02       Impact factor: 2.267

9.  Early results of bladder-cancer screening in a high-risk population of heavy smokers.

Authors:  Hannes Steiner; Maria Bergmeister; Irmgard Verdorfer; Thomas Granig; Gregor Mikuz; Georg Bartsch; Brigitte Stoehr; Andrea Brunner
Journal:  BJU Int       Date:  2008-03-11       Impact factor: 5.588

10.  Patterns of hematuria referral to urologists: does a gender disparity exist?

Authors:  Emilie K Johnson; Stephanie Daignault; Yingxi Zhang; Cheryl T Lee
Journal:  Urology       Date:  2008-07-10       Impact factor: 2.649

View more
  12 in total

1.  Gender, race, and variation in the evaluation of microscopic hematuria among Medicare beneficiaries.

Authors:  Jeffrey C Bassett; JoAnn Alvarez; Tatsuki Koyama; Matthew Resnick; Chaochen You; Shenghua Ni; David F Penson; Daniel A Barocas
Journal:  J Gen Intern Med       Date:  2014-12-02       Impact factor: 5.128

2.  Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer.

Authors:  Jacob T Ark; JoAnn R Alvarez; Tatsuki Koyama; Jeffrey C Bassett; William J Blot; Michael T Mumma; Matthew J Resnick; Chaochen You; David F Penson; Daniel A Barocas
Journal:  J Urol       Date:  2017-06-24       Impact factor: 7.450

3.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

4.  Diagnostic impact of dysmorphic red blood cells on evaluating microscopic hematuria: the urologist's perspective.

Authors:  Kyo Chul Koo; Kwang Suk Lee; Ah Ran Choi; Koon Ho Rha; Sung Joon Hong; Byung Ha Chung
Journal:  Int Urol Nephrol       Date:  2016-03-28       Impact factor: 2.370

5.  Microhematuria in Postmenopausal Women: Adherence to Guidelines in a Tertiary Care Setting.

Authors:  Megan S Bradley; Marcella G Willis-Gray; Cindy L Amundsen; Nazema Y Siddiqui
Journal:  J Urol       Date:  2015-10-30       Impact factor: 7.450

Review 6.  The association between symptoms and bladder or renal tract cancer in primary care: a systematic review.

Authors:  Mia Schmidt-Hansen; Sabine Berendse; William Hamilton
Journal:  Br J Gen Pract       Date:  2015-11       Impact factor: 5.386

7.  A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.

Authors:  Laimonis Kavalieris; Paul J O'Sullivan; James M Suttie; Brent K Pownall; Peter J Gilling; Christophe Chemasle; David G Darling
Journal:  BMC Urol       Date:  2015-03-27       Impact factor: 2.264

8.  Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.

Authors:  Tony Lough; Qingyang Luo; Carthika Luxmanan; Alastair Anderson; Jimmy Suttie; Paul O'Sullivan; David Darling
Journal:  BMC Urol       Date:  2018-03-09       Impact factor: 2.264

9.  Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Authors:  Agata Ptaszynska; Samuel M Cohen; Edward M Messing; Timothy P Reilly; Eva Johnsson; Kristina Johnsson
Journal:  Diabetes Ther       Date:  2015-09-01       Impact factor: 2.945

10.  Quality of the diagnostic process in patients presenting with symptoms suggestive of bladder or kidney cancer: a systematic review.

Authors:  Yin Zhou; Marije van Melle; Hardeep Singh; Willie Hamilton; Georgios Lyratzopoulos; Fiona M Walter
Journal:  BMJ Open       Date:  2019-10-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.